Phenazine Cations as Anticancer Theranostics†

Felicity F Noakes1,2, Kirsty L Smitten1,3, Laura E C Maple2

  • 1Department of Chemistry, The University of Sheffield, Western Bank, Sheffield S3 7HF, U.K.

Insights

Two novel polypyridyl organic cations show selective cancer cell toxicity and enhanced photoactivity. The more active cation induces lysosome-dependent cell death at nanomolar concentrations with minimal animal toxicity.

Area of Science:

  • Medicinal Chemistry
  • Photochemistry
  • Cell Biology

Background:

  • Polypyridyl compounds are versatile ligands for photoactive metal complexes.
  • Investigating their biological properties is crucial for therapeutic applications.
  • Understanding structure-activity relationships guides the design of novel agents.

Purpose of the Study:

  • To investigate the biological properties and therapeutic potential of two water-soluble polypyridyl organic cations.
  • To evaluate their cytotoxicity, cellular uptake, and mechanism of action.
  • To assess their preliminary toxicity in an animal model.

Main Methods:

  • Cytotoxicity screening across various cell lines.
  • Cellular uptake studies using intrinsic luminescence.
  • Confocal microscopy and stimulated emission depletion (STED) nanoscopy.
  • Transmission electron microscopy (TEM) for ultrastructural analysis.
  • Galleria melonella toxicity assay.

Main Results:

  • Both cations exhibited selective cytotoxicity against cancer cells versus HEK293 cells.
  • The more extended cation showed enhanced photoactivity, inducing cell death at nanomolar concentrations upon visible light irradiation.
  • Cellular uptake studies revealed preferential internalization of the more lipophilic cation.
  • Treatment led to lysosomal swelling, mitochondrial dysfunction, and lysosome-dependent cell death (necrosis and apoptosis).
  • No detectable toxicity was observed in the Galleria melonella model up to 80 mg/kg.

Conclusions:

  • Polypyridyl organic cations represent a promising class of photoactive compounds for therapeutic development.
  • The active cation demonstrates potent, light-activated cytotoxicity with a favorable preliminary safety profile.
  • Further investigation is warranted to explore their therapeutic efficacy and optimize their design.

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
272
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
198
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
160
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
264